Estudio multicéntrico de deterioro cognitivo en lupus eritematoso sistémico: ECLES
Palabras clave:
lupus eritematoso sistémico, disfunción cognitiva en lupus, lupus neuropsiquiátrico
Resumen
Introducción: Los pacientes lúpicos presentan un riesgo incrementado de deterioro cognitivo (DC) comparado con individuos sanos, el cual puede ser debido a múltiples causas.Objetivo: Describir la frecuencia y características del deterioro cognitivo en pacientes con lupus sin manifestaciones neuropsiquiátricas conocidas.Materiales y método: Se incluyeron pacientes de 16 a 55 años con diagnóstico de LES según criterios del Colegio Americano de Reumatología (ACR) de 1997. Se incluyeron test neuropsicológicos acordes a la propuesta del ACR y el cuestionario de Beck para evaluar depresión. Se definió DC a valores de <2 o más desvíos estándar comparada con la media de población normal en al menos un test. Se consideró focal cuando afectó una o más medidas de un dominio y multifocal en 2 o más dominios. Para comparar proporciones se utilizó prueba exacta de Fisher y para comparar variables numéricas se usó prueba de Kruskal-Wallis. Se consideró significativo un valor de p <0,05.Citas
I. American College of Rheumatology Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis and Rheumatism 1999; 42(4):599-608.
II. Bertsias GK, Ioannidis JP, Aringer M, Bollen E, Bombardieri S, Bruce IN, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis 2010, 69:2074-2082.
III. Hanly JG, Urowitz MB, Su L, Bae SC, Gordon C, Wallace DJ, et al. Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 2010; 69: 529-35.
IV. Kozora E, Hanly JG, Lapteva L and Filley CM. Cognitive dysfunction in systemic lupus erythematosus. Arthritis and Rheumatism 2008; 58(11):3286-3298.
V. Kosora E, Erkan D, Zhang L, Zimmerman R, Ra mon G, Ulug AM, et al. Cognitive dysfunction in antiphospholipid antibody (aPL)-negative systemic lupus erythematosus (SLE) versus aPLpositive non-SLE patients. Clin Exp Rheumatol 2014; 32(1):34-40.
VI. Gladman DD, Urowitz MB, Goldsmith CH, Fortin P, Ginzler E, Gordon C, et al. The reliability of the Systemic Lupus International Collaborating Clinics/ American College of Rheumatology Damage Index for systemic lupus erythematosus. Arthritis Rheum 1997; 40:809-813.
VII. Bombardier C, Gladman DD, Urowitz MB, Caron D and Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on prognosis studies in SLE. Arthritis Rheum 1992; 35:630-640.
VIII. Gladman DD, Urowitz MB, Goldsmith CH, Fortin P, Ginzler E, Gordon C, et al. The reliability of the Systemic Lupus International Collaborating Clinics/ American College of Rheumatology Damage Index for systemic lupus erythematosus. Arthritis Rheum 1997; 40:809-813.
IX. Kozora E, Ellison MC and West S. Reliability and validity of the proposed American College of Rheumatology neuropsychological battery for systemic lupus erythematosus. Arthritis Rheum 2004; 51:810-818.
X. Folstein MF, Folstein SE and McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatric Res 1975; 12:189-198.
XI. Butman J, Arizaga RL, Harris P, Drake M, Baumann D, dePacale A, et al. El “Mini Mental State Examination” en Español. Normas para Buenos Aires. Rev Neurol Arg 2001; 26(1):11-15.
XII. Reitan RM. Validity of the Trail Making Test as an indication of organic brain damage. Percept Mot Skills 1958; 8:271-276.
XIII. Raúl L. Arizaga, Deterioro cognitivo y demencias. Buenos Aires, Argentina: ediciones Polemos 2011, 185-195.
XIV. Delis DC, Kramer JH, Kaplan E and Ober BA. California Verbal Learning Test: Adult Version Manual. San Antonio, TX: The Psychological Corporation (1987).
XV. Wechsler D. Wechsler Adult Intelligence Scale- 3 edition (WAIS-III). San Antonio, TX: Psychological Corporation; 1997.
XVI. Butman J, Allegri RF, Harris P y Drake M. Fluencia verbal en español, datos normativos en Argentina. Medicina (Buenos Aires) 2000; 60:561-564.
XVII. Mangone CA, Grillo R, Saavedra L y Pallo V. Nuevas variables de evaluación del Test del Reloj. Vértex 2005; XVI: 13-19.
XVIII. Rey A. Test de copie et de reproduction de memoire de figures geometriques complexes. Paris. Centre de Psychologie Applquee 1959.
XIX. Ad Hoc Committee on lupus response criteria: cognition sub-committee, Mikdashi J, Esdaile JM, Alarcón GS, Crofford L, Fessler BJ, Shanberg L, et al. Proposed response criteria for neurocognitive impairment in systemic lupus erythematosus clinical trials. Lupus 2007; 16: 418-425.
XX. Beck AT, Steer RA and Brown GK (1996) "Manual for the Beck Depression Inventory-II". San Antonio, TX: Psychological Corporation.
XXI. Alarcón GS, Cianfrini L, Bradley LA, Sanchez ML, Brooks k, Friedman AW, et al. Systemic lupus erythematosus in three ethnic groups X. Measuring cognitive impairment with the cognitive symptoms inventory. Arthritis and Rheumatism 2002; 47(3):310-319.
XXII. Hanly JG, Su L, Omisade A, Farewell VT and Fisk JD. Screening for cognitive impairment in systemic lupus erythematosus. J Rheumatol. 2012;
39(7):1371-7.
XXIII. Petri M, Naqibuddin N, Carson KA, Wallace DJ, Weisman MH, Holliday SL, et al. Depression and cognitive impairment in newly diagnosed systemic lupus erythematosus.J Rheumatol 2010;37(10):2032-8.
XXIV. Utset TO, Fink J and Doninger NA. Prevalence of neurocognitive dysfunction and other clinical manifestations in disabled patients with systemic lupus erythematosus. J Rheumatol 2006; 33:531-538.
XXV. Conti F, Alessandri C, Perricone C, Scrivo R, Rezai S, Ceccarelli F, et al. (2012) Neurocognitive Dysfunction in Systemic Lupus Erythematosus: Association with Antiphospholipid Antibodies, Disease Activity and Chronic Damage. PLoS ONE 7(3): e33824. doi:10.1371/journal.pone.0033824.
XXVI. Pons-Estel BA, Catoggio LJ, Cardiel MH, Soriano ER, Gentiletti S, Villa AR, et al. The GLADEL multinational Latin American prospective inception cohort of 1,214 patients with systemic lupus erythematosus: ethnic and disease heterogeneity among “Hispanics”. Medicine (Baltimore) 2004; 83:1-17.
II. Bertsias GK, Ioannidis JP, Aringer M, Bollen E, Bombardieri S, Bruce IN, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis 2010, 69:2074-2082.
III. Hanly JG, Urowitz MB, Su L, Bae SC, Gordon C, Wallace DJ, et al. Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 2010; 69: 529-35.
IV. Kozora E, Hanly JG, Lapteva L and Filley CM. Cognitive dysfunction in systemic lupus erythematosus. Arthritis and Rheumatism 2008; 58(11):3286-3298.
V. Kosora E, Erkan D, Zhang L, Zimmerman R, Ra mon G, Ulug AM, et al. Cognitive dysfunction in antiphospholipid antibody (aPL)-negative systemic lupus erythematosus (SLE) versus aPLpositive non-SLE patients. Clin Exp Rheumatol 2014; 32(1):34-40.
VI. Gladman DD, Urowitz MB, Goldsmith CH, Fortin P, Ginzler E, Gordon C, et al. The reliability of the Systemic Lupus International Collaborating Clinics/ American College of Rheumatology Damage Index for systemic lupus erythematosus. Arthritis Rheum 1997; 40:809-813.
VII. Bombardier C, Gladman DD, Urowitz MB, Caron D and Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on prognosis studies in SLE. Arthritis Rheum 1992; 35:630-640.
VIII. Gladman DD, Urowitz MB, Goldsmith CH, Fortin P, Ginzler E, Gordon C, et al. The reliability of the Systemic Lupus International Collaborating Clinics/ American College of Rheumatology Damage Index for systemic lupus erythematosus. Arthritis Rheum 1997; 40:809-813.
IX. Kozora E, Ellison MC and West S. Reliability and validity of the proposed American College of Rheumatology neuropsychological battery for systemic lupus erythematosus. Arthritis Rheum 2004; 51:810-818.
X. Folstein MF, Folstein SE and McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatric Res 1975; 12:189-198.
XI. Butman J, Arizaga RL, Harris P, Drake M, Baumann D, dePacale A, et al. El “Mini Mental State Examination” en Español. Normas para Buenos Aires. Rev Neurol Arg 2001; 26(1):11-15.
XII. Reitan RM. Validity of the Trail Making Test as an indication of organic brain damage. Percept Mot Skills 1958; 8:271-276.
XIII. Raúl L. Arizaga, Deterioro cognitivo y demencias. Buenos Aires, Argentina: ediciones Polemos 2011, 185-195.
XIV. Delis DC, Kramer JH, Kaplan E and Ober BA. California Verbal Learning Test: Adult Version Manual. San Antonio, TX: The Psychological Corporation (1987).
XV. Wechsler D. Wechsler Adult Intelligence Scale- 3 edition (WAIS-III). San Antonio, TX: Psychological Corporation; 1997.
XVI. Butman J, Allegri RF, Harris P y Drake M. Fluencia verbal en español, datos normativos en Argentina. Medicina (Buenos Aires) 2000; 60:561-564.
XVII. Mangone CA, Grillo R, Saavedra L y Pallo V. Nuevas variables de evaluación del Test del Reloj. Vértex 2005; XVI: 13-19.
XVIII. Rey A. Test de copie et de reproduction de memoire de figures geometriques complexes. Paris. Centre de Psychologie Applquee 1959.
XIX. Ad Hoc Committee on lupus response criteria: cognition sub-committee, Mikdashi J, Esdaile JM, Alarcón GS, Crofford L, Fessler BJ, Shanberg L, et al. Proposed response criteria for neurocognitive impairment in systemic lupus erythematosus clinical trials. Lupus 2007; 16: 418-425.
XX. Beck AT, Steer RA and Brown GK (1996) "Manual for the Beck Depression Inventory-II". San Antonio, TX: Psychological Corporation.
XXI. Alarcón GS, Cianfrini L, Bradley LA, Sanchez ML, Brooks k, Friedman AW, et al. Systemic lupus erythematosus in three ethnic groups X. Measuring cognitive impairment with the cognitive symptoms inventory. Arthritis and Rheumatism 2002; 47(3):310-319.
XXII. Hanly JG, Su L, Omisade A, Farewell VT and Fisk JD. Screening for cognitive impairment in systemic lupus erythematosus. J Rheumatol. 2012;
39(7):1371-7.
XXIII. Petri M, Naqibuddin N, Carson KA, Wallace DJ, Weisman MH, Holliday SL, et al. Depression and cognitive impairment in newly diagnosed systemic lupus erythematosus.J Rheumatol 2010;37(10):2032-8.
XXIV. Utset TO, Fink J and Doninger NA. Prevalence of neurocognitive dysfunction and other clinical manifestations in disabled patients with systemic lupus erythematosus. J Rheumatol 2006; 33:531-538.
XXV. Conti F, Alessandri C, Perricone C, Scrivo R, Rezai S, Ceccarelli F, et al. (2012) Neurocognitive Dysfunction in Systemic Lupus Erythematosus: Association with Antiphospholipid Antibodies, Disease Activity and Chronic Damage. PLoS ONE 7(3): e33824. doi:10.1371/journal.pone.0033824.
XXVI. Pons-Estel BA, Catoggio LJ, Cardiel MH, Soriano ER, Gentiletti S, Villa AR, et al. The GLADEL multinational Latin American prospective inception cohort of 1,214 patients with systemic lupus erythematosus: ethnic and disease heterogeneity among “Hispanics”. Medicine (Baltimore) 2004; 83:1-17.
Publicado
2015-06-01
Cómo citar
1.
D’Amico M. Estudio multicéntrico de deterioro cognitivo en lupus eritematoso sistémico: ECLES. Rev. Argent. Reumatol. [Internet]. 1 de junio de 2015 [citado 26 de abril de 2024];26(2):28 -32. Disponible en: https://ojs.reumatologia.org.ar/index.php/revistaSAR/article/view/631
Sección
Artículo Original
Derechos de autor 2015 A nombre de los autores. Derechos de reproducción: Sociedad Argentina de Reumatología
Esta obra está bajo licencia internacional Creative Commons Reconocimiento-NoComercial-SinObrasDerivadas 4.0.
